IBDEI0BT ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5343,2)
 ;;=^5015561
 ;;^UTILITY(U,$J,358.3,5344,0)
 ;;=N07.3^^27^344^25
 ;;^UTILITY(U,$J,358.3,5344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5344,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,5344,1,4,0)
 ;;=4^N07.3
 ;;^UTILITY(U,$J,358.3,5344,2)
 ;;=^5015562
 ;;^UTILITY(U,$J,358.3,5345,0)
 ;;=N07.3^^27^344^26
 ;;^UTILITY(U,$J,358.3,5345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5345,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,5345,1,4,0)
 ;;=4^N07.3
 ;;^UTILITY(U,$J,358.3,5345,2)
 ;;=^5015562
 ;;^UTILITY(U,$J,358.3,5346,0)
 ;;=N07.4^^27^344^23
 ;;^UTILITY(U,$J,358.3,5346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5346,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,5346,1,4,0)
 ;;=4^N07.4
 ;;^UTILITY(U,$J,358.3,5346,2)
 ;;=^5015563
 ;;^UTILITY(U,$J,358.3,5347,0)
 ;;=N07.5^^27^344^27
 ;;^UTILITY(U,$J,358.3,5347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5347,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,5347,1,4,0)
 ;;=4^N07.5
 ;;^UTILITY(U,$J,358.3,5347,2)
 ;;=^5015564
 ;;^UTILITY(U,$J,358.3,5348,0)
 ;;=N07.6^^27^344^22
 ;;^UTILITY(U,$J,358.3,5348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5348,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,5348,1,4,0)
 ;;=4^N07.6
 ;;^UTILITY(U,$J,358.3,5348,2)
 ;;=^5015565
 ;;^UTILITY(U,$J,358.3,5349,0)
 ;;=N07.7^^27^344^28
 ;;^UTILITY(U,$J,358.3,5349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5349,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,5349,1,4,0)
 ;;=4^N07.7
 ;;^UTILITY(U,$J,358.3,5349,2)
 ;;=^5015566
 ;;^UTILITY(U,$J,358.3,5350,0)
 ;;=N07.8^^27^344^31
 ;;^UTILITY(U,$J,358.3,5350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5350,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ oth morphologic lesions
 ;;^UTILITY(U,$J,358.3,5350,1,4,0)
 ;;=4^N07.8
 ;;^UTILITY(U,$J,358.3,5350,2)
 ;;=^5015567
 ;;^UTILITY(U,$J,358.3,5351,0)
 ;;=N07.9^^27^344^32
 ;;^UTILITY(U,$J,358.3,5351,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5351,1,3,0)
 ;;=3^Hereditary nephropathy, NEC w/ unsp morphologic lesions
 ;;^UTILITY(U,$J,358.3,5351,1,4,0)
 ;;=4^N07.9
 ;;^UTILITY(U,$J,358.3,5351,2)
 ;;=^5015568
 ;;^UTILITY(U,$J,358.3,5352,0)
 ;;=N08.^^27^344^21
 ;;^UTILITY(U,$J,358.3,5352,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5352,1,3,0)
 ;;=3^Glomerular disorders in diseases classified elsewhere
 ;;^UTILITY(U,$J,358.3,5352,1,4,0)
 ;;=4^N08.
 ;;^UTILITY(U,$J,358.3,5352,2)
 ;;=^5015569
 ;;^UTILITY(U,$J,358.3,5353,0)
 ;;=C90.00^^27^345^9
 ;;^UTILITY(U,$J,358.3,5353,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5353,1,3,0)
 ;;=3^Multiple myeloma not having achieved remission
 ;;^UTILITY(U,$J,358.3,5353,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,5353,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,5354,0)
 ;;=C90.01^^27^345^8
 ;;^UTILITY(U,$J,358.3,5354,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5354,1,3,0)
 ;;=3^Multiple myeloma in remission
 ;;^UTILITY(U,$J,358.3,5354,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,5354,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,5355,0)
 ;;=C90.02^^27^345^7
 ;;^UTILITY(U,$J,358.3,5355,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5355,1,3,0)
 ;;=3^Multiple myeloma in relapse
 ;;^UTILITY(U,$J,358.3,5355,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,5355,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,5356,0)
 ;;=E11.29^^27^345^20
